SERDA Therapeutics develops a wound debridement solution specifically designed to treat severe burn injuries and persistent ulcers.
SERDA therapeutics has raised $2.2M in total funding. The most recent round was Seed. The last funding was announced in June 2024.
SERDA therapeutics's investors include NLC.
SERDA therapeutics is headquartered in Amsterdam, The Netherlands.
SERDA Therapeutics develops a wound debridement solution specifically designed to treat severe burn injuries and persistent ulcers.
SERDA therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SERDA therapeutics — Funding & Investors." VCBacked, June 3, 2024, https://www.vcbacked.co/company/serda-therapeutics. Accessed August 14, 2026.
VCBacked. (2024). SERDA therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/serda-therapeutics
{{cite web |title=SERDA therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/serda-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated